NRNP 6566
Las últimas cargas en NRNP 6566. ¿Buscando notas en NRNP 6566? Tenemos muchas notas, guias de estudio y notas de estudio disponsible para tu escuela.
-
729
- 0
-
75
All courses for NRNP 6566
-
NRNP 6566 2
-
NRNP 6566 727
-
NRNP-6566 2
Último contenido NRNP 6566
NRNP 6566 WEEK 3 KNOWLEDGE CHECK Q&AS BEST EXAM SOLUTION LATEST DOWNLOADS 2022/2023
- Examen
- • 15 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 2 fuera de 15 páginas
Preparando tu documento...
NRNP 6566 WEEK 3 KNOWLEDGE CHECK Q&AS BEST EXAM SOLUTION LATEST DOWNLOADS 2022/2023
NRNP 6566 WK1-5 Midterm Exam With 
Complete Solution Graded A+ 
Describe cytochrome p450 system - Answer Cytochrome p450 system is a series of 
enzymes used to metabolize medications 
Inhibitors - Answer block metabolic activity from one or more CYP450 enzymes 
Inducers - Answer increase CYP450 enzyme activity by increasing enzyme synthesis 
Describe effect on low and high albumin levels on active drug levels especially for drugs 
that are highly protein bound - Answer Albumin is the plasma prot...
- Examen
- • 6 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 2 fuera de 6 páginas
Preparando tu documento...
NRNP 6566 WK1-5 Midterm Exam With 
Complete Solution Graded A+ 
Describe cytochrome p450 system - Answer Cytochrome p450 system is a series of 
enzymes used to metabolize medications 
Inhibitors - Answer block metabolic activity from one or more CYP450 enzymes 
Inducers - Answer increase CYP450 enzyme activity by increasing enzyme synthesis 
Describe effect on low and high albumin levels on active drug levels especially for drugs 
that are highly protein bound - Answer Albumin is the plasma prot...
1. Describe the cytochrome P450 system. Describe how inducers and inhibitors affect the 
cytochrome system and how that affects the half-life of medications. 
a. Cytochrome p450 system is a series of enzymes used to metabolize medications. 
b. Drugs that cause CYP450 metabolic drug interactions are referred to as either inhibitors 
or inducers. Inducers increase CYP450 enzyme activity by increasing enzyme 
synthesis 
c. Inhibitors block the metabolic activity of one or more CYP450 enzymes 
2. De...
- Examen
- • 40 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 4 fuera de 40 páginas
Preparando tu documento...
1. Describe the cytochrome P450 system. Describe how inducers and inhibitors affect the 
cytochrome system and how that affects the half-life of medications. 
a. Cytochrome p450 system is a series of enzymes used to metabolize medications. 
b. Drugs that cause CYP450 metabolic drug interactions are referred to as either inhibitors 
or inducers. Inducers increase CYP450 enzyme activity by increasing enzyme 
synthesis 
c. Inhibitors block the metabolic activity of one or more CYP450 enzymes 
2. De...
NRNP 6566 week 1 to 5 Key Concepts. 
 
NRNP 6566 
Key Concepts Week 1 to 5 
 
 
Week 1 
1.	Describe the cytochrome P450 system. Describe how inducers and inhibitors affect the cytochrome system and how that affects the half-life of medications. 
a.	Cytochrome p450 system is a series of enzymes used to metabolize medications. 
b.	Drugs that cause CYP450 metabolic drug interactions are referred to as either inhibitors or inducers. Inducers increase CYP450 enzyme activity by increasing enzyme synth...
- Examen
- • 38 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 4 fuera de 38 páginas
Preparando tu documento...
NRNP 6566 week 1 to 5 Key Concepts. 
 
NRNP 6566 
Key Concepts Week 1 to 5 
 
 
Week 1 
1.	Describe the cytochrome P450 system. Describe how inducers and inhibitors affect the cytochrome system and how that affects the half-life of medications. 
a.	Cytochrome p450 system is a series of enzymes used to metabolize medications. 
b.	Drugs that cause CYP450 metabolic drug interactions are referred to as either inhibitors or inducers. Inducers increase CYP450 enzyme activity by increasing enzyme synth...
NRNP 6566 WK1-5 Midterm Exam 
Describe cytochrome p450 system Ans- Cytochrome p450 system is a series of enzymes used to 
metabolize medications 
Inhibitors Ans- block metabolic activity from one or more CYP450 enzymes 
Inducers Ans- increase CYP450 enzyme activity by increasing enzyme synthesis 
Describe effect on low and high albumin levels on active drug levels especially for drugs that are highly 
protein bound Ans- Albumin is the plasma protein with the greatest capacity for binding drugs...
- Examen
- • 7 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 2 fuera de 7 páginas
Preparando tu documento...
NRNP 6566 WK1-5 Midterm Exam 
Describe cytochrome p450 system Ans- Cytochrome p450 system is a series of enzymes used to 
metabolize medications 
Inhibitors Ans- block metabolic activity from one or more CYP450 enzymes 
Inducers Ans- increase CYP450 enzyme activity by increasing enzyme synthesis 
Describe effect on low and high albumin levels on active drug levels especially for drugs that are highly 
protein bound Ans- Albumin is the plasma protein with the greatest capacity for binding drugs...
NRNP 6566 WK 10 Knowledge Check. 
 
 
 
A 57 year old female is admitted to the oncology unit for chemotherapy related to her to acute leukemia. Her initial dose of chemo was 2 days ago. While rounding today, the patients tells the NP that she feels so weak. The NP notes her heart rate is 44 today (down from 68 2 days ago). She has had less than 100 cc of urine out over the last 24 hours. 
 
Labs from this morning include: 
 
LAB DATA: 
-Sodium 131 
-Potassium 7.8 
-Chloride 105 
-Bicarbonate 1...
- Examen
- • 9 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 2 fuera de 9 páginas
Preparando tu documento...
NRNP 6566 WK 10 Knowledge Check. 
 
 
 
A 57 year old female is admitted to the oncology unit for chemotherapy related to her to acute leukemia. Her initial dose of chemo was 2 days ago. While rounding today, the patients tells the NP that she feels so weak. The NP notes her heart rate is 44 today (down from 68 2 days ago). She has had less than 100 cc of urine out over the last 24 hours. 
 
Labs from this morning include: 
 
LAB DATA: 
-Sodium 131 
-Potassium 7.8 
-Chloride 105 
-Bicarbonate 1...
NRNP 6566 week 6 knowledge check. 
 
 
 
 
A 54 year old female has a 30 year pack smoking history. She recently underwent pulmonary function testing which showed moderate obstructive lung disease. What would your treatment plan (including medications) include for this patient? 
 
 
Correct 
Answer: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 suggests that smoking cessation should be immediately pursued if the patient is still smoking. Nicotine replacement (gum, inhal...
- Examen
- • 8 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 2 fuera de 8 páginas
Preparando tu documento...
NRNP 6566 week 6 knowledge check. 
 
 
 
 
A 54 year old female has a 30 year pack smoking history. She recently underwent pulmonary function testing which showed moderate obstructive lung disease. What would your treatment plan (including medications) include for this patient? 
 
 
Correct 
Answer: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 suggests that smoking cessation should be immediately pursued if the patient is still smoking. Nicotine replacement (gum, inhal...
NRNP 6566 Week 5 Knowledge Check 
 
QUESTION 1 
1.	A 54-year women is 3 days post abdominal surgery for removal of a cancerous mass in her abdomen. She develops acute shortness of breath associated with tachycardia and hypotension. CT Scan of the chest is positive for multiple small pulmonary embolism. What medication and dosing would you order initially to treat the pulmonary embolism? 
 
This patient should be given fondaparinuc (Arixtra) subcutaneously. Dosing is weight- based: 
1.	5 mg SQ on...
- Examen
- • 4 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 1 fuera de 4 páginas
Preparando tu documento...
NRNP 6566 Week 5 Knowledge Check 
 
QUESTION 1 
1.	A 54-year women is 3 days post abdominal surgery for removal of a cancerous mass in her abdomen. She develops acute shortness of breath associated with tachycardia and hypotension. CT Scan of the chest is positive for multiple small pulmonary embolism. What medication and dosing would you order initially to treat the pulmonary embolism? 
 
This patient should be given fondaparinuc (Arixtra) subcutaneously. Dosing is weight- based: 
1.	5 mg SQ on...
NRNP 6566Week 4 knowledge check. 
 
 
 
 
A 47 year old male admitted with an infected elbow wound. On his second day in the hospital you find him in his room confused and agitated. 
 
Vital signs are as follows: 
Temperature – 96.2 °F 
Pulse -140 beats per minute Respirations – 40 breaths per minute Blood Pressure – 90/40 mmHg 
Labs include a WBC count of 3,000 Pt weighs 185 pounds 
Further assessment of him includes: 
 
Urine output of 100cc for the last 8 hours Pulse oximetry of 88% o...
- Examen
- • 7 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 2 fuera de 7 páginas
Preparando tu documento...
NRNP 6566Week 4 knowledge check. 
 
 
 
 
A 47 year old male admitted with an infected elbow wound. On his second day in the hospital you find him in his room confused and agitated. 
 
Vital signs are as follows: 
Temperature – 96.2 °F 
Pulse -140 beats per minute Respirations – 40 breaths per minute Blood Pressure – 90/40 mmHg 
Labs include a WBC count of 3,000 Pt weighs 185 pounds 
Further assessment of him includes: 
 
Urine output of 100cc for the last 8 hours Pulse oximetry of 88% o...
NRNP 6566 Knowledge Check Week 3 
 
Amiodarone has possible complex interactions with multiple medications. It has an effect on warfarin metabolism. Amiodarone is a potent inhibitor of cytochrome P450 enzymes and inhibition of these enzymes will cause an increased plasma concentration and decreased clearance; thereby increasing the prothrombin time and INR placing the patient at increased risk for bleeding complications. Hence, when given 
together, warfarin dose should be decreased and frequent...
- Examen
- • 7 páginas's •
-
NRNP 6566•NRNP 6566
Vista previa 2 fuera de 7 páginas
Preparando tu documento...
NRNP 6566 Knowledge Check Week 3 
 
Amiodarone has possible complex interactions with multiple medications. It has an effect on warfarin metabolism. Amiodarone is a potent inhibitor of cytochrome P450 enzymes and inhibition of these enzymes will cause an increased plasma concentration and decreased clearance; thereby increasing the prothrombin time and INR placing the patient at increased risk for bleeding complications. Hence, when given 
together, warfarin dose should be decreased and frequent...